Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of DA-020
NCT07402330Phase 1Withdrawn
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of Mucinex Full Force Nasal Spray in Chemotherapy-induced alopecia (CIA) (3 arms). Primary endpoint: Concentration of DA-020 in Serum at 24 hours. Planned start Apr 2026; status: withdrawn.
02
Drugs
Mucinex Full Force Nasal Spray
03
Conditions
Chemotherapy-induced alopecia (CIA)
Beyond the preview
Go deeper on NCT07402330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07402330.